QLM3003 vs upadacitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: JAK · full Atopic Dermatitis pipeline
QLM3003
Developed by Qilu Pharmaceutical
NCT06058000 · Phase 2 · completed
The study was randomized, quadruple-blind, placebo-controlled, and enrolled 120 participants, with a clinical disease-activity endpoint (EASI-75). However, no primary endpoint results or statistical comparison are available, so the trial provides well-designed but currently incomplete evidence.
Next expected readout: March 2027 · NCT06880276 (registry estimate)
No aligned efficacy figure on record for this race.
upadacitinib · Rinvoq
Marketed by AbbVie
NCT03607422 · Phase 3 · completed
Participants were randomized and the trial was quadruple-blinded and placebo-controlled in 912 adolescents and adults. Both co-primary endpoints -- a 75% reduction in the validated Eczema Area and Severity Index (EASI75) and clearance or near-clearance on the validated Investigator Global Assessment -- were clearly met for both upadacitinib doses versus placebo at week 16 (p<0.001 for all comparisons).
Next expected readout: November 2026 · NCT06389136 (registry estimate)
Reported efficacy
Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16 (Baseline and Week 16); Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16 (Baseline and Week 16): EASI-75 response at week 16 (Measure Up 2): 60.1% (upadacitinib 15 mg) vs 72.9% (upadacitinib 30 mg) vs 13.3% (placebo). (met)
Result source: NCT03607422
Results for Atopic Dermatitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | QLM3003 | upadacitinib |
|---|---|---|
| EASI-75 | —Trial running · NCT06880276 | 60.1% vs 13.3%+46.8 vs placeboNCT0360742263 other results
|
| IGA 0/1 with 2-point improvement | —Trial running · NCT06880276 | —Trial running · NCT03568318 |
| EASI-90 | —Trial running · NCT06880276 | 42.4% vs 5.4%+37 vs placeboNCT0360742214 other results
|
| EASI, % change | —Trial running · NCT06880276 | -74.1% vs -34.5%−39.6 vs placeboNCT0360742269 other results
|
EASI-75
- QLM3003
- —Trial running · NCT06880276
- upadacitinib
- 60.1% vs 13.3%+46.8 vs placeboNCT03607422
63 other results
- 69.6% vs 16.3% NCT03569293
- 72.9% vs 13.3% NCT03607422
- 79.7% vs 16.3% NCT03569293
- 72.4% vs 62.6% NCT03738397
- 33% vs 3.6% NCT03607422
- 38.1% vs 3.6% NCT03569293
- 44% vs 3.6% NCT03607422
- 47.4% vs 3.6% NCT03569293
- 69% vs 13.3% NCT03607422
- 74.6% vs 12.1% NCT03569293
- 37.9% vs 6.7% NCT03607422
- 39.7% vs 3.4% NCT03569293
- 73.4% vs 13.3% NCT03607422
- 84.5% vs 12.1% NCT03569293
- 53.2% vs 6.7% NCT03607422
- 55.8% vs 3.4% NCT03569293
- 44.3% vs 18.2% NCT03738397
- 52.4% vs 9.8% NCT02925117
- 52.4% vs 7.3% NCT02925117
- 69% vs 9.8% NCT02925117
- 81% vs 7.3% NCT02925117
- 28.6% vs 9.8% NCT02925117
- 31% vs 7.3% NCT02925117
- 0% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 50% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 0% vs 11.1% NCT02925117
- 12.5% vs 11.1% NCT02925117
- 100% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 80% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 66.7% vs 100% NCT02925117
- 50% vs 100% NCT02925117
- 66.7% vs 100% NCT02925117
- 0% vs 100% NCT02925117
- 50% vs 100% NCT02925117
- 100% vs 100% NCT02925117
- 50% vs 100% NCT02925117
- 50% vs 100% NCT02925117
- 85.7% vs 100% NCT02925117
- 33.3% vs 100% NCT02925117
- 33.3% vs 100% NCT02925117
- 12.5% vs 11.1% NCT02925117
- 20% vs 11.1% NCT02925117
- 25% vs 11.1% NCT02925117
- 0% vs 100% NCT02925117
- 33.3% vs 100% NCT02925117
- 0% vs 11.1% NCT02925117
- 9.1% vs 11.1% NCT02925117
IGA 0/1 with 2-point improvement
- QLM3003
- —Trial running · NCT06880276
- upadacitinib
- —Trial running · NCT03568318
EASI-90
- QLM3003
- —Trial running · NCT06880276
- upadacitinib
- 42.4% vs 5.4%+37 vs placeboNCT03607422
14 other results
- 53.1% vs 8.1% NCT03569293
- 58.5% vs 5.4% NCT03607422
- 65.8% vs 8.1% NCT03569293
- 48.3% vs 1.7% NCT03607422
- 47.6% vs 3.4% NCT03569293
- 62% vs 1.7% NCT03607422
- 74.1% vs 3.4% NCT03569293
- 61.6% vs 40.3% NCT03738397
- 26.2% vs 2.4% NCT02925117
- 26.2% vs 0% NCT02925117
- 50% vs 2.4% NCT02925117
- 45.2% vs 0% NCT02925117
- 14.3% vs 2.4% NCT02925117
- 9.5% vs 0% NCT02925117
EASI, % change
- QLM3003
- —Trial running · NCT06880276
- upadacitinib
- -74.1% vs -34.5%−39.6 vs placeboNCT03607422
69 other results
- -80.2% vs -40.7% NCT03569293
- -84.7% vs -34.5% NCT03607422
- -87.7% vs -40.7% NCT03569293
- -77.8% vs -42.2% NCT03607422
- -82.1% vs -43.5% NCT03569293
- -84.8% vs -42.2% NCT03607422
- -89.4% vs -43.5% NCT03569293
- -61.7% vs -23% NCT02925117
- -74.4% vs -23% NCT02925117
- -39.4% vs -23% NCT02925117
- 617.5% vs -37.7% NCT02925117
- 99.3% vs -37.7% NCT02925117
- 614% vs -37.3% NCT02925117
- 130.2% vs -37.3% NCT02925117
- 614.6% vs -35.8% NCT02925117
- 104.1% vs -35.8% NCT02925117
- 613.8% vs -29.8% NCT02925117
- 104.1% vs -29.8% NCT02925117
- 608.8% vs -31.2% NCT02925117
- 154.1% vs -31.2% NCT02925117
- 613.3% vs -2.3% NCT02925117
- 151.7% vs -2.3% NCT02925117
- 607.3% vs 13.5% NCT02925117
- 72.6% vs 13.5% NCT02925117
- 582.3% vs 50.7% NCT02925117
- 65.7% vs 50.7% NCT02925117
- -65.4% vs -17.5% NCT02925117
- -84.6% vs -37.7% NCT02925117
- 769.7% vs -37.7% NCT02925117
- 39% vs -37.7% NCT02925117
- -90.3% vs -37.3% NCT02925117
- 787.8% vs -37.3% NCT02925117
- 24.4% vs -37.3% NCT02925117
- -91.4% vs -35.8% NCT02925117
- 802.1% vs -35.8% NCT02925117
- 63.6% vs -35.8% NCT02925117
- -90.1% vs -29.8% NCT02925117
- 799.5% vs -29.8% NCT02925117
- -13.3% vs -29.8% NCT02925117
- -92% vs -31.2% NCT02925117
- 778.9% vs -31.2% NCT02925117
- 140.6% vs -31.2% NCT02925117
- -69.6% vs 13.5% NCT02925117
- -73.8% vs 50.7% NCT02925117
- -82.8% vs -17.5% NCT02925117
- -83.1% vs -2.3% NCT02925117
- 771.5% vs -2.3% NCT02925117
- -28.8% vs -2.3% NCT02925117
- -67.5% vs 13.5% NCT02925117
- 898.5% vs 13.5% NCT02925117
- 181.5% vs -2.3% NCT02925117
- 63.5% vs -2.3% NCT02925117
- 189.6% vs 13.5% NCT02925117
- 59% vs 13.5% NCT02925117
- 186% vs 50.7% NCT02925117
- 79.1% vs 50.7% NCT02925117
- -43.7% vs -17.5% NCT02925117
- 11.8% vs 50.7% NCT02925117
- 791.5% vs 50.7% NCT02925117
- 170.7% vs -37.7% NCT02925117
- 69.1% vs -37.7% NCT02925117
- 201.4% vs -37.3% NCT02925117
- 77.7% vs -37.3% NCT02925117
- 179.9% vs -35.8% NCT02925117
- 71.8% vs -35.8% NCT02925117
- 189.1% vs -29.8% NCT02925117
- 74.4% vs -29.8% NCT02925117
- 200.9% vs -31.2% NCT02925117
- 77.6% vs -31.2% NCT02925117
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
QLM3003: no structured comparison results are available for Atopic Dermatitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. QLM3003: 0 of 4 rows · upadacitinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | upadacitinib |
|---|---|
| Dropout rate | —15 mga NCT03607422 · Phase 3 show 48 more results—15 mg NCT03607422 · Phase 3 5.2%15 mg QD NCT03607422 · Phase 3 —15 mg NCT03607422 · Phase 3 —15 mg NCT03607422 · Phase 3 4.1%15 mg QD NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 3.2%30 mg QD NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 4.5%30 mg QD NCT03607422 · Phase 3 —15 mg NCT03569293 · Phase 3 —15 mg QD NCT03569293 · Phase 3 0%15 mg QD NCT03569293 · Phase 3 —15 mg NCT03569293 · Phase 3 —15 mg NCT03569293 · Phase 3 3.3%15 mg QD NCT03569293 · Phase 3 —30 mg NCT03569293 · Phase 3 —30 mg QD NCT03569293 · Phase 3 0%30 mg QD NCT03569293 · Phase 3 —30 mg NCT03569293 · Phase 3 —30 mg NCT03569293 · Phase 3 4.9%30 mg QD NCT03569293 · Phase 3 5.2%15 mg NCT05507580 · Phase 4 · registry result, not featured evidence —15 mg NCT05507580 · Phase 4 · registry result, not featured evidence —15 mg then 30 mg NCT05507580 · Phase 4 · registry result, not featured evidence 2.6%30 mg NCT05507580 · Phase 4 · registry result, not featured evidence —30 mg then 15 mg NCT05507580 · Phase 4 · registry result, not featured evidence —30 mg NCT05507580 · Phase 4 · registry result, not featured evidence 10.5%30 mg NCT04195698 · Phase 3 · registry result, not featured evidence 16.5%30 mg NCT04195698 · Phase 3 · registry result, not featured evidence 8.8%30 mg QD NCT03738397 · Phase 3 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence 11.9%15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 7.1%30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence 26.2%7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —15 mga NCT03607422 · Phase 3 show 48 more results—15 mg NCT03607422 · Phase 3 3.4%15 mg QD NCT03607422 · Phase 3 —15 mg NCT03607422 · Phase 3 —15 mg NCT03607422 · Phase 3 1.2%15 mg QD NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 0%30 mg QD NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 —30 mg NCT03607422 · Phase 3 0.4%30 mg QD NCT03607422 · Phase 3 —15 mg NCT03569293 · Phase 3 —15 mg QD NCT03569293 · Phase 3 0%15 mg QD NCT03569293 · Phase 3 —15 mg NCT03569293 · Phase 3 —15 mg NCT03569293 · Phase 3 0.4%15 mg QD NCT03569293 · Phase 3 —30 mg NCT03569293 · Phase 3 —30 mg QD NCT03569293 · Phase 3 0%30 mg QD NCT03569293 · Phase 3 —30 mg NCT03569293 · Phase 3 —30 mg NCT03569293 · Phase 3 1.6%30 mg QD NCT03569293 · Phase 3 —15 mg NCT05507580 · Phase 4 · registry result, not featured evidence —15 mg NCT05507580 · Phase 4 · registry result, not featured evidence —15 mg then 30 mg NCT05507580 · Phase 4 · registry result, not featured evidence —30 mg NCT05507580 · Phase 4 · registry result, not featured evidence —30 mg then 15 mg NCT05507580 · Phase 4 · registry result, not featured evidence —30 mg NCT05507580 · Phase 4 · registry result, not featured evidence 1.7%30 mg NCT04195698 · Phase 3 · registry result, not featured evidence 4.7%30 mg NCT04195698 · Phase 3 · registry result, not featured evidence 2%30 mg QD NCT03738397 · Phase 3 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence 2.4%15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 4.8%30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence 7.1%7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 15.4%15 mga NCT03607422 · Phase 3 show 48 more results10.9%15 mg NCT03607422 · Phase 3 3.4%15 mg QD NCT03607422 · Phase 3 10.6%15 mg NCT03607422 · Phase 3 16.6%15 mg NCT03607422 · Phase 3 1.2%15 mg QD NCT03607422 · Phase 3 13.8%30 mg NCT03607422 · Phase 3 16.9%30 mg NCT03607422 · Phase 3 0%30 mg QD NCT03607422 · Phase 3 17.3%30 mg NCT03607422 · Phase 3 17.4%30 mg NCT03607422 · Phase 3 2.8%30 mg QD NCT03607422 · Phase 3 3.3%15 mg NCT03569293 · Phase 3 12.5%15 mg QD NCT03569293 · Phase 3 3.1%15 mg QD NCT03569293 · Phase 3 14.7%15 mg NCT03569293 · Phase 3 14.3%15 mg NCT03569293 · Phase 3 2.1%15 mg QD NCT03569293 · Phase 3 22.2%30 mg NCT03569293 · Phase 3 10.9%30 mg QD NCT03569293 · Phase 3 0%30 mg QD NCT03569293 · Phase 3 20%30 mg NCT03569293 · Phase 3 18.4%30 mg NCT03569293 · Phase 3 3.3%30 mg QD NCT03569293 · Phase 3 3.5%15 mg NCT05507580 · Phase 4 · registry result, not featured evidence 1.4%15 mg NCT05507580 · Phase 4 · registry result, not featured evidence 0.7%15 mg then 30 mg NCT05507580 · Phase 4 · registry result, not featured evidence 0%30 mg NCT05507580 · Phase 4 · registry result, not featured evidence 0.8%30 mg then 15 mg NCT05507580 · Phase 4 · registry result, not featured evidence 0%30 mg NCT05507580 · Phase 4 · registry result, not featured evidence 5.9%30 mg NCT04195698 · Phase 3 · registry result, not featured evidence 5.5%30 mg NCT04195698 · Phase 3 · registry result, not featured evidence 4.1%30 mg QD NCT03738397 · Phase 3 · registry result, not featured evidence 2.4%15 mg NCT02925117 · Phase 2 · registry result, not featured evidence 2.4%15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence —15 mg NCT02925117 · Phase 2 · registry result, not featured evidence 6.1%30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 0%30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence —30 mg NCT02925117 · Phase 2 · registry result, not featured evidence 4.8%7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence 4.8%7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence —7.5 mg NCT02925117 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 15 mga covid-19 23.1% (placebo 0%) acne 19.2% (placebo 3.3%) dermatitis atopic 19.2% (placebo 13.3%) NCT03607422 · Phase 3 show 38 more results15 mg covid-19 27.3% (placebo 0%) upper respiratory tract infection 21.8% (placebo 1.7%) acne 18.2% (placebo 3.3%) NCT03607422 · Phase 3 15 mg QD acne 10.3% (placebo 3.3%) upper respiratory tract infection 10.3% (placebo 1.7%) oropharyngeal pain 6.9% (placebo 0%) NCT03607422 · Phase 3 15 mg covid-19 31.7% (placebo 0%) acne 19.2% (placebo 3.3%) blood creatine phosphokinase increased 17.3% (placebo 1.7%) NCT03607422 · Phase 3 15 mg covid-19 31.9% (placebo 0%) dermatitis atopic 17.9% (placebo 13.3%) upper respiratory tract infection 14.4% (placebo 1.7%) NCT03607422 · Phase 3 15 mg QD acne 12.8% (placebo 3.3%) headache 7% (placebo 3.3%) nasopharyngitis 6.2% (placebo 3.3%) NCT03607422 · Phase 3 30 mg covid-19 41.4% (placebo 0%) acne 34.5% (placebo 3.3%) dermatitis atopic 24.1% (placebo 13.3%) NCT03607422 · Phase 3 30 mg covid-19 32.2% (placebo 0%) blood creatine phosphokinase increased 18.6% (placebo 1.7%) acne 11.9% (placebo 3.3%) NCT03607422 · Phase 3 30 mg QD acne 14.5% (placebo 3.3%) blood creatine phosphokinase increased 9.7% (placebo 1.7%) headache 8.1% (placebo 3.3%) NCT03607422 · Phase 3 30 mg covid-19 39.4% (placebo 0%) acne 25% (placebo 3.3%) dermatitis atopic 15.4% (placebo 13.3%) NCT03607422 · Phase 3 30 mg covid-19 29.8% (placebo 0%) blood creatine phosphokinase increased 18.3% (placebo 1.7%) dermatitis atopic 14.9% (placebo 13.3%) NCT03607422 · Phase 3 30 mg QD acne 15% (placebo 3.3%) nasopharyngitis 8.1% (placebo 3.3%) headache 6.5% (placebo 3.3%) NCT03607422 · Phase 3 15 mg covid-19 20% (placebo 0%) acne 16.7% (placebo 1.6%) blood creatine phosphokinase increased 16.7% (placebo 3.3%) NCT03569293 · Phase 3 15 mg QD covid-19 25% (placebo 0%) upper respiratory tract infection 21.9% (placebo 8.2%) blood creatine phosphokinase increased 12.5% (placebo 3.3%) NCT03569293 · Phase 3 15 mg QD acne 14.1% (placebo 1.6%) blood creatine phosphokinase increased 7.8% (placebo 3.3%) headache 7.8% (placebo 3.3%) NCT03569293 · Phase 3 15 mg covid-19 38.2% (placebo 0%) dermatitis atopic 18.6% (placebo 3.3%) upper respiratory tract infection 18.6% (placebo 8.2%) NCT03569293 · Phase 3 15 mg covid-19 28.6% (placebo 0%) nasopharyngitis 16.5% (placebo 1.6%) dermatitis atopic 16% (placebo 3.3%) NCT03569293 · Phase 3 15 mg QD upper respiratory tract infection 9.6% (placebo 8.2%) nasopharyngitis 7.9% (placebo 1.6%) acne 5.4% (placebo 1.6%) NCT03569293 · Phase 3 30 mg acne 37% (placebo 1.6%) upper respiratory tract infection 33.3% (placebo 8.2%) dermatitis atopic 29.6% (placebo 3.3%) NCT03569293 · Phase 3 30 mg QD covid-19 35.9% (placebo 0%) acne 28.1% (placebo 1.6%) upper respiratory tract infection 28.1% (placebo 8.2%) NCT03569293 · Phase 3 30 mg QD acne 15.6% (placebo 1.6%) upper respiratory tract infection 12.5% (placebo 8.2%) blood creatine phosphokinase increased 7.8% (placebo 3.3%) NCT03569293 · Phase 3 30 mg covid-19 38.1% (placebo 0%) acne 22.9% (placebo 1.6%) blood creatine phosphokinase increased 17.1% (placebo 3.3%) NCT03569293 · Phase 3 30 mg covid-19 35.1% (placebo 0%) acne 18.9% (placebo 1.6%) dermatitis atopic 18% (placebo 3.3%) NCT03569293 · Phase 3 30 mg QD acne 16.5% (placebo 1.6%) upper respiratory tract infection 12.8% (placebo 8.2%) nasopharyngitis 11.5% (placebo 1.6%) NCT03569293 · Phase 3 15 mg acne 7% nasopharyngitis 5.7% upper respiratory tract infection 3.5% NCT05507580 · Phase 4 · registry result, not featured evidence 15 mg nasopharyngitis 11.1% dermatitis atopic 8.3% upper respiratory tract infection 6.9% NCT05507580 · Phase 4 · registry result, not featured evidence 15 mg then 30 mg dermatitis atopic 16% nasopharyngitis 4.2% acne 2.8% NCT05507580 · Phase 4 · registry result, not featured evidence 30 mg acne 13.8% nasopharyngitis 9.1% dermatitis atopic 3.9% NCT05507580 · Phase 4 · registry result, not featured evidence 30 mg then 15 mg dermatitis atopic 12% nasopharyngitis 7.5% acne 6% NCT05507580 · Phase 4 · registry result, not featured evidence 30 mg dermatitis atopic 16.5% acne 6.6% eczema 5.5% NCT05507580 · Phase 4 · registry result, not featured evidence 30 mg acne 20.5% covid-19 13.4% blood creatine phosphokinase increased 13% NCT04195698 · Phase 3 · registry result, not featured evidence 30 mg acne 22.9% dermatitis atopic 19.1% blood creatine phosphokinase increased 14.8% NCT04195698 · Phase 3 · registry result, not featured evidence 30 mg QD acne 18.7% dermatitis atopic 10.5% blood creatine phosphokinase increased 7.6% NCT03738397 · Phase 3 · registry result, not featured evidence 15 mg upper respiratory tract infection 16.7% (placebo 5.4%) dermatitis atopic 11.9% (placebo 2.2%) nasopharyngitis 11.9% (placebo 1.1%) NCT02925117 · Phase 2 · registry result, not featured evidence 15 mg upper respiratory tract infection 11.9% (placebo 5.4%) nasopharyngitis 9.5% (placebo 1.1%) blood creatine phosphokinase increased 7.1% (placebo 3.2%) NCT02925117 · Phase 2 · registry result, not featured evidence 30 mg upper respiratory tract infection 22.8% (placebo 5.4%) dermatitis atopic 19.3% (placebo 2.2%) acne 11.4% (placebo 1.1%) NCT02925117 · Phase 2 · registry result, not featured evidence 30 mg acne 14.3% (placebo 1.1%) upper respiratory tract infection 11.9% (placebo 5.4%) blood creatine phosphokinase increased 9.5% (placebo 3.2%) NCT02925117 · Phase 2 · registry result, not featured evidence 7.5 mg upper respiratory tract infection 16.7% (placebo 5.4%) dermatitis atopic 14.3% (placebo 2.2%) acne 9.5% (placebo 1.1%) NCT02925117 · Phase 2 · registry result, not featured evidence 7.5 mg upper respiratory tract infection 16.7% (placebo 5.4%) dermatitis atopic 11.9% (placebo 2.2%) acne 9.5% (placebo 1.1%) NCT02925117 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
upadacitinib
show 63 more results
show 7 more results
show 38 more results
show 14 more results
show 7 more results
show 8 more results
show 7 more results
show 69 more results
show 7 more results
show 7 more results
show 13 more results
show 7 more results
+ 25 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: QLM3003's landscape · upadacitinib's landscape